NCT00322036

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 800 (actual)
• Sponsor: Myrexis Inc. · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.

Conditions

• Alzheimer Disease
• Dementia

Interventions

Type	Name	Description
DRUG	MPC-7869	Oral 800 mg BID
DRUG	MPC-7869	Oral BID dosing

Timeline

• Start date: 2006-05-01
• Completion: 2008-12-01
• First posted: 2006-05-04
• Last updated: 2008-08-05

Locations

92 sites across 12 countries: United States, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom